FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer By Ogkologos - July 8, 2026 126 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the POTOMAC study Source RELATED ARTICLESMORE FROM AUTHOR Perioperative Durvalumab Plus FLOT Improves OS in Patients with Resectable Gastric or GEJ Adenocarcinoma Advancing Childhood Cancer Research: A Conversation with Dr. Brigitte Widemann Azacitidine-Venetoclax Prolongs EFS Over Induction Chemotherapy Among Induction-Eligible Patients with AML MOST POPULAR Five Questions With…Francisco. March 17, 2022 Coronavirus reports – Part 7: “I’m more concerned about the second... November 24, 2020 The Growths On This Woman’s Lips Are A Sign That She... April 17, 2020 Molecular Analysis for Precision Oncology Congress 2023, 4–6 October 2023 Paris,... September 26, 2023 Load more HOT NEWS Charity promotes eco-fashion with collection at Love Not Landfill pop-up FDA Approves Teclistamab in Combination with Daratumumab Hyaluronidase-fihj for Relapsed or... Helping Kids with Cancer Speak for the Supportive Care They Need Brentuximab Approved for High-Risk Hodgkin Lymphoma in Children and Adolescents
